Statute Details
- Title: Medicines (Advertisements for Licensable Healthcare Services) (Exemption) Order 2023
- Act Code: MA1975-S818-2023
- Legislative Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines Act 1975 (specifically section 51(4)(b))
- Enacting Authority: Minister for Health
- Made Date: 20 November 2023
- Commencement: 18 December 2023
- Current Status: Current version as at 27 March 2026
- Key Provisions: Sections 1–4 (citation/commencement, definition, exemption, revocation)
- Related Legislation: Healthcare Services Act 2020; Medicines Act 1975
What Is This Legislation About?
The Medicines (Advertisements for Licensable Healthcare Services) (Exemption) Order 2023 is a targeted regulatory instrument that clarifies when certain advertisements are exempt from a medicines advertising restriction under the Medicines Act 1975. In practical terms, it addresses a compliance question that often arises for healthcare providers: when a licensed healthcare provider promotes its services, does that promotion fall within the Medicines Act’s controls on “advertisements” relating to medicines?
Under the Medicines Act 1975, section 51(1)(b) generally restricts advertisements in a way that can capture promotional content connected to medicines. However, the Order creates a specific exemption: it removes the application of section 51(1)(b) to advertisements published (or caused to be published) by persons licensed under the Healthcare Services Act 2020 to provide “licensable healthcare services”.
The Order therefore supports a regulatory balance. It preserves the Medicines Act’s advertising framework, while recognising that licensed healthcare providers should be able to advertise their licensable healthcare services without triggering the medicines advertising prohibition—provided the advertisement is published by, or on behalf of, the relevant licensed provider.
What Are the Key Provisions?
Section 1 (Citation and commencement) sets out the formal name of the instrument and its effective date. The Order is cited as the “Medicines (Advertisements for Licensable Healthcare Services) (Exemption) Order 2023” and comes into operation on 18 December 2023. For practitioners, the commencement date matters when assessing whether an advertisement published before that date would have been governed by the earlier exemption regime (see section 4 below).
Section 2 (Definition) defines the key term “licensable healthcare service” by reference to the Healthcare Services Act 2020. This cross-reference is important because it ties the exemption to the licensing taxonomy under the Healthcare Services Act. In other words, the exemption is not open-ended: it only applies to services that qualify as “licensable healthcare services” under the 2020 Act.
From a legal drafting perspective, this approach reduces ambiguity. Instead of attempting to restate the scope of licensable services within the Order, the legislature incorporates the definition from the primary healthcare licensing statute. For compliance work, counsel should therefore confirm that the advertised service is indeed within the category of “licensable healthcare service” as defined under the Healthcare Services Act 2020.
Section 3 (Exemption from section 51(1)(b) of Act) is the operative provision. It provides that section 51(1)(b) of the Medicines Act 1975 does not apply to an advertisement published or caused to be published by a person who is licensed under the Healthcare Services Act 2020 to provide any licensable healthcare service.
Several practical elements are embedded in this exemption:
- Advertisement trigger: The exemption is tied to an “advertisement” (as that term is understood in the Medicines Act framework). The Order does not redefine “advertisement”, so the general statutory interpretation under the Medicines Act and related guidance would likely apply.
- Publisher/causer requirement: The exemption applies where the advertisement is published or caused to be published by the licensed person. “Caused to be published” is significant: it can capture situations where a licensed provider engages an advertising agency, marketing firm, or third-party platform to publish promotional material on its behalf.
- Licensing requirement: The advertiser must be a person licensed under the Healthcare Services Act 2020. This means the exemption is not automatically available to unlicensed operators, even if they provide healthcare services in practice.
- Service scope requirement: The licensed person must be licensed to provide any licensable healthcare service. The exemption is therefore linked to the provider’s licensing permissions, not merely to the fact that the provider is “in healthcare”.
For lawyers advising on advertising compliance, the key question becomes: does the advertisement relate to a licensable healthcare service provided by a properly licensed entity, and is that entity the publisher or the person who caused the advertisement to be published? If both are satisfied, the medicines advertising prohibition in section 51(1)(b) is displaced.
Section 4 (Revocation) revokes the earlier exemption instrument: Medicines (Advertisements by Healthcare Institutions) (Exemption) Order 2004 (G.N. No. S 279/2004). This indicates a legislative shift from a “healthcare institutions” framing in 2004 to the current “licensable healthcare services” and licensing structure under the Healthcare Services Act 2020.
Revocation is not merely administrative. It affects transitional compliance analysis. Advertisements made after 18 December 2023 should be assessed under the 2023 Order, not the 2004 Order. Where there is a dispute about the applicable regime, the commencement date and the revocation clause become central.
How Is This Legislation Structured?
This Order is concise and structured as a four-section instrument:
- Section 1: Citation and commencement (sets the effective date and name).
- Section 2: Definition (defines “licensable healthcare service” by reference to the Healthcare Services Act 2020).
- Section 3: Substantive exemption (disapplies section 51(1)(b) of the Medicines Act 1975 for qualifying licensed providers and advertisements).
- Section 4: Revocation (removes the earlier 2004 exemption order).
Because the Order is short, it functions as a targeted “switch” in the Medicines Act advertising regime rather than a comprehensive advertising code. Practitioners should therefore read it together with the underlying provisions of the Medicines Act 1975 and the licensing framework under the Healthcare Services Act 2020.
Who Does This Legislation Apply To?
The exemption applies to persons licensed under the Healthcare Services Act 2020 to provide licensable healthcare services. This includes healthcare providers that hold the relevant licences under the 2020 Act. The Order does not specify categories of providers (e.g., hospitals, clinics, or other service types) because the licensing framework itself determines which services are “licensable” and who may provide them.
In addition, the exemption is relevant to advertising practices involving third parties. Since the exemption covers advertisements “published or caused to be published” by the licensed person, it can extend to marketing arrangements where the licensed provider directs or authorises publication through agents or contractors. However, the exemption’s availability still depends on the licensed status of the person who caused the advertisement to be published and the service being within the scope of licensable healthcare services.
Why Is This Legislation Important?
This Order is important because it reduces regulatory friction at the intersection of medicines advertising law and healthcare service licensing. Without the exemption, licensed healthcare providers might have faced uncertainty about whether their service promotions could be treated as falling within the Medicines Act’s advertising restrictions—potentially leading to delays, compliance costs, or overly cautious marketing practices.
From an enforcement and compliance perspective, the exemption provides a clearer legal basis for lawful advertising by licensed healthcare providers. It also signals the legislature’s intent to align advertising permissions with the modern healthcare licensing regime under the Healthcare Services Act 2020. In effect, the licensing status becomes the gatekeeper for whether the Medicines Act’s section 51(1)(b) restriction applies.
For practitioners, the Order’s practical impact is most visible in advising on:
- Advertising approvals and legal review: determining whether a proposed advertisement is exempt from section 51(1)(b) based on the advertiser’s licence and the nature of the service.
- Third-party marketing arrangements: assessing whether the “caused to be published” language captures agency-led campaigns and how contractual responsibility should be allocated.
- Transitional issues: confirming that the 2023 Order governs advertisements after 18 December 2023, given the revocation of the 2004 exemption order.
Finally, because the exemption is specific to section 51(1)(b), counsel should not assume it eliminates all advertising restrictions under other provisions of the Medicines Act or other healthcare-related regulatory frameworks. The exemption is a targeted disapplication, not a blanket advertising permission.
Related Legislation
- Healthcare Services Act 2020
- Medicines Act 1975 (including section 51(1)(b) and section 51(4)(b))
- Medicines (Advertisements by Healthcare Institutions) (Exemption) Order 2004 (G.N. No. S 279/2004) — revoked
Source Documents
This article provides an overview of the Medicines (Advertisements for Licensable Healthcare Services) (Exemption) Order 2023 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.